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Multicenter Pilot Treatment Trial for Psychogenic
Nonepileptic Seizures
A Randomized Clinical Trial
W. Curt LaFrance Jr, MD, MPH; Grayson L. Baird, MS; John J. Barry, MD; Andrew S. Blum, MD, PhD;
Anne Frank Webb, MA; Gabor I. Keitner, MD; Jason T. Machan, PhD; Ivan Miller, PhD; Jerzy P. Szaflarski, MD, PhD;
for the NES Treatment Trial (NEST-T) Consortium

IMPORTANCE There is a paucity of controlled treatment trials for the treatment of conversion
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disorder, seizures type, also known as psychogenic nonepileptic seizures (PNES).
Psychogenic nonepileptic seizures, the most common conversion disorder, are as disabling as
epilepsy and are not adequately addressed or treated by mental health clinicians.
OBJECTIVE To evaluate different PNES treatments compared with standard medical care
(treatment as usual).
DESIGN, SETTING, AND PARTICIPANTS Pilot randomized clinical trial at 3 academic medical
centers with mental health clinicians trained to administer psychotherapy or
psychopharmacology to outpatients with PNES. Thirty-eight participants were randomized in
a blocked schedule among 3 sites to 1 of 4 treatment arms and were followed up for 16 weeks
between September 2008 and February 2012; 34 were included in the analysis.
INTERVENTIONS Medication (flexible-dose sertraline hydrochloride) only, cognitive

behavioral therapy informed psychotherapy (CBT-ip) only, CBT-ip with medication
(sertraline), or treatment as usual.
MAIN OUTCOMES AND MEASURES Seizure frequency was the primary outcome; psychosocial
and functioning measures, including psychiatric symptoms, social interactions, quality of life,
and global functioning, were secondary outcomes. Data were collected prospectively, weekly,
and with baseline, week 2, midpoint (week 8), and exit (week 16) batteries. Within-group
analyses for each arm were performed on primary (seizure frequency) and secondary
outcomes from treatment-blinded raters using an intention-to-treat analysis.
RESULTS The psychotherapy (CBT-ip) arm showed a 51.4% seizure reduction (P = .01) and
significant improvement from baseline in secondary measures including depression, anxiety,
quality of life, and global functioning (P < .001). The combined arm (CBT-ip with sertraline)
showed 59.3% seizure reduction (P = .008) and significant improvements in some secondary
measures, including global functioning (P = .007). The sertraline-only arm did not show a
reduction in seizures (P = .08). The treatment as usual group showed no significant seizure
reduction or improvement in secondary outcome measures (P = .19).
CONCLUSIONS AND RELEVANCE This pilot randomized clinical trial for PNES revealed
significant seizure reduction and improved comorbid symptoms and global functioning with
CBT-ip for PNES without and with sertraline. There were no improvements in the
sertraline-only or treatment-as-usual arms. This study supports the use of manualized
psychotherapy for PNES and successful training of mental health clinicians in the treatment.
Future studies could assess larger-scale intervention dissemination.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT00835627
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P

sychogenic nonepileptic seizures (PNES) are a somatoform conversion disorder manifesting as paroxysmal
events not associated with electroencephalographic
(EEG) epileptiform correlates, and they have psychological
underpinnings.1 They are not responsive to treatment with, and
may be worsened by, antiepileptic drugs.2,3 They occur worldwide, and in the United States up to 20% of civilians and up to
25% of veterans diagnosed as having epilepsy actually have
PNES,4 making PNES as common as multiple sclerosis and Parkinson disease5 and as disabling as epilepsy.6 The phenomenology and psychological underpinnings of PNES are well delineated, including an understanding of risk factors and
prognostic features.7 Much less is known, however, about effective treatments for PNES, resulting in many patients returning to neurology offices and emergency departments because of recurrent seizures. Surveys administered to American
Epilepsy Society members and UK clinicians described standard medical care (treatment as usual [TAU]) for PNES as a neurologist sharing the diagnosis with the patient and family, if
present, while continuing to follow up with the patient, tapering the antiepileptic drug in lone PNES, and the majority not
initiating psychotropic treatment but making a referral to a psychiatrist or psychologist.8,9 Many times after diagnosis, patients with PNES do not pursue mental health care follow-up
or they receive only supportive psychotherapy, which is not
effective for PNES10 or for depression.11,12
Prior pilot treatment trials revealed that sertraline hydrochloride or cognitive behavioral therapy (CBT) may be effective in reducing PNES. Patients receiving sertraline reported
a 45% reduction in PNES, compared with an 8% increase in
PNES in the placebo group.13 An open-label psychotherapy
study for PNES10 used an epilepsy therapy workbook14 modified to target dysfunctional cognitions and behaviors in patients with PNES.15 Eleven of 17 individual therapy intervention completers (65%) reported no seizures by the end of the
12-week trial. The 12-session, therapist-guided seizure treatment workbook focused on gaining control of seizures and included training in healthy communication, understanding
medications, conducting functional behavioral analysis, and
examining internal and external triggers. In addition to seizure reduction, mean scores on scales measuring depression,
anxiety, somatic symptoms, quality of life (QOL), and psychosocial functioning showed improvement from baseline to the
final session, suggesting that the intervention also improved
psychiatric symptoms, QOL, and functioning.
Despite PNES (formerly referred to as pseudoseizures or hysteroepilepsy) being recognized for centuries,16 a fully powered phase 3 intervention randomized clinical trial (RCT) has
not yet been conducted. Although the National Institutes of
Health Epilepsy Benchmarks identified developing evidencebased treatment for PNES as a priority,17 no standards for a generalizable, effective, widespread treatment for PNES are available. Thus, we have conducted a pilot RCT designed to evaluate
various treatments for PNES. The secondary aims of the study
included evaluating the impact of treatment on psychiatric
symptoms, QOL, coping, and general and relational functioning and assessing the ability to disseminate the treatment to
other sites.
998

Methods
The study was approved by the organizing site, Rhode Island
Hospital, and by the Stanford University and University of Cincinnati institutional review boards. All enrollees provided written informed consent.
Participants aged 18 to 65 years with a video EEG–
confirmed diagnosis of lone PNES and at least 1 event in the
month prior were recruited between September 2008 and February 2012 (Figure 1). Criteria for the diagnosis of events consisted of stereotypic motor manifestations with or without
change in level of consciousness.18 Exclusion criteria included the following: concurrent mixed epilepsy and PNES or
equivocal video EEG findings in discerning between epileptic
seizures and PNES; use of monoamine oxidase inhibitor or
pimozide within 30 days prior to study entry; current use of
sumatriptan succinate or other serotonin 1 receptor agonist;
allergy or sensitivity to sertraline; current enrollment in CBT
for PNES; current or past-year self-mutilation; frank psychosis; current suicidality with intent to harm self; serious illness; active substance or alcohol use or dependence that could
interfere with participation; pending litigation; and current application for long-term disability.

Study Design
Participants were randomized 1:1:1:1 into 1 of 4 treatment arms
using a computer-generated blocked randomization. Enrollment was at Rhode Island Hospital initially (n = 28) and continued in 2010 when 2 other sites were added (Stanford University, n = 7; University of Cincinnati, n = 3), as designed in
the dissemination infrastructure grant. Patients were randomized to psychotherapy for seizures (CBT informed psychotherapy [CBT-ip]; n = 9), flexible-dose sertraline (n = 9), combined CBT-ip and sertraline (n = 10), or TAU (n = 10). Sertraline
was chosen because of its limited drug-drug interactions with
antiepileptic drugs and because of its US Food and Drug Administration indications for the many diagnostic comorbidities occurring with PNES (eg, depression, anxiety, posttraumatic stress disorder).
A complete history and medical, psychiatric, and neurological examinations were obtained before or at enrollment.
Clinician-rated assessments and self-report questionnaires
measuring psychiatric symptoms, social interactions, QOL, and
global functioning were given at baseline, treatment initiation (week 2), midpoint (week 8), and exit (week 16). As is the
case in all seizure trials and because seizures are the source of
disability, seizure frequency was selected as the primary
outcome.19 Seizure frequency was assessed daily using weekly
seizure calendars, with family assisting participants in logging seizure frequency, triggers, and medical care utilization.
Sertraline hydrochloride was started on day 14 and titrated up
to 200 mg or as tolerated. The psychotherapy was administered in 12 weekly, 1-hour, individual sessions by 1 trained therapist per site starting on day 14 using the modified workbook
from the previous open-label study.10 Uniformity of treatment between sites was assured with pretreatment training;
all therapists underwent one-on-one training with the prin-
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Figure 1. CONSORT Flow Diagram of the Multisite Pilot Randomized Clinical Trial for Psychogenic Nonepileptic
Seizures, Comparing Sertraline and/or Cognitive Behavioral Therapy Informed Psychotherapy (CBT-ip)
With Treatment as Usual
589 Assessed for eligibility
551 Excluded
508 Not meeting inclusion criteria
43 Declined to participate
3 Dropped out day after
enrollment and received
no treatment

38 Randomized

28 Allocated to interventions
9 Sertraline hydrochloride, 25-200 mg/d
9 CBT-ip
10 CBT-ip and sertraline

10 Allocated to control (standard medical care/
treatment as usual)

27 Received allocated intervention
1 Did not receive allocated intervention (CBT-ip)
1 Withdrew (CBT-ip)

7 Received allocated intervention
3 Did not receive allocated intervention
3 Withdrew

1 Lost to follow-up (could not be reached)
1 Discontinued intervention (exited for other
treatment)

2 Lost to follow-up (could not be reached)
3 Discontinued intervention (wanted to start
other treatment)

27 Analyzed
1 Excluded from intention-to-treat analysis
(did not complete baseline after signing
consent)

7 Analyzed
3 Excluded from intention-to-treat analysis
(did not complete baseline after signing
consent)

cipal investigator (W.C.L.) on the CBT-ip intervention and
treated 2 patients with PNES prior to the trial, with all sessions filmed for weekly feedback provided by the principal investigator. Participants in the TAU arm followed up with their
treating neurologist and were seen biweekly for assessments,
in the same manner as those in the other treatment arms.
Throughout the study, therapy sessions from all sites were reviewed for treatment fidelity. Treatment providers demonstrated adherence and competence using a modified Cognitive Therapy Scale20 and a Psychotherapy Rating Scale21 used
in the prior trial10 before delivering treatment and during treatment across sites. Video EEG diagnosis between the 3 sites was
independently validated, with excellent interrater reliability
(κ = 1.00). Participants also provided comments and feedback in exit interviews, which were assessed using qualitative methods.
Self-report assessments included the Beck Depression Inventory–II, Beck Anxiety Inventory, Barratt Impulsiveness
Scale, Davidson Trauma Scale, Dissociative Experiences Scale,
Side Effects Profile, Symptom Checklist 90, Quality of Life in
Epilepsy Inventory 31, QOL Burden to Family Scale, Expectations Scale, and Ways of Coping Questionnaire. Clinicianrated assessments included the Global Assessment of Functioning, Hamilton Depression Rating Scale, Oxford Handicap
Scale, Clinical Global Impressions–Improvement, Clinical
Global Impressions–Severity, and Longitudinal Interval Follow-up Evaluation–Range of Impaired Functioning Tool (a qualjamapsychiatry.com

ity-of-relationships measure). Treatment-blinded trained raters assessed clinician-scored outcomes after reliability was
established. Interrater reliability was established by having raters score a sample of the same patients and having the results
reviewed. Given the nature of interventions delivery, clinicians in the study were not blinded to the intervention.

Statistical Analysis
Generalized linear mixed models for negative binomial and Poisson data were used to model seizure counts and emergency department visits, respectively, as a function of treatment condition and time (PROC GLIMMIX; SAS version 9.3 statistical
software; SAS Institute, Inc). Classic sandwich estimation was
used to adjust for any model misspecification. This analysis technique was chosen because of its versatility in modeling individual trajectories of count data over time.
Linear trends were used to test significance of trajectories
on secondary measures across the 4 ordinal assessment periods using PROC GLIMMIX. The linear trends across these ordinal assessments were compared between groups using orthogonal linear contrasts. For clinical relevance, difference means, 95%
confidence intervals, and effect sizes are also presented.
Multiple comparisons were examined with orthogonal linear contrasts with α maintained at .05 using the Holm method.
Because mixed modeling calculates individual trajectories for
each participant and final seizure counts were unavailable for
only 2 patients, this provided the intention-to-treat approach
JAMA Psychiatry September 2014 Volume 71, Number 9
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Table 1. Patient Medical History Obtained by Interview and Record Reviewa
CBT-ip
(n = 9)

Characteristic

CBT-ip With
Sertraline
(n = 9)

Sertraline
(n = 9)

TAU
(n = 7)

Sociodemographic, self-reported
Age, mean (SD), y

37.9 (11.5)

39.1 (13.2)

39.7 (11.7)

41.6 (8.3)

Age at NES onset, mean (SD), y

33.6 (10.7)

36.7 (13.9)

33.2 (11.9)

39.1 (7.7)

Female, No. (%)

7 (77.8)

Education, mean (SD), y

15.4 (3.9)

9 (100.0)

8 (88.9)

15.7 (2.4)

13.0 (1.9)

7 (100.0)
16.0 (3.6)

Currently employed, No. (%)

2 (22.2)

6 (66.7)

2 (22.2)

2 (28.6)

Currently receiving disability, No. (%)

3 (33.3)

3 (33.3)

4 (44.4)

5 (71.4)

Currently married, No. (%)

4 (44.4)

6 (66.7)

4 (44.4)

2 (28.6)

Currently driving, No. (%)

3 (33.3)

0

3 (33.3)

3 (42.9)

Mood disordersc

3 (33.3)

7 (77.8)

9 (100.0)

4 (57.1)

Anxiety disordersd

6 (85.7)

7 (87.5)

7 (100.0)

7 (100.0)

Somatoform disorders other than NES

1 (12.5)

3 (37.5)

2 (28.6)

3 (42.9)

Impulsivity, cluster B

1 (11.1)

1 (11.1)

3 (33.3)

2 (28.6)

Obsessive-compulsive personality disorder,
cluster C

0

2 (22.2)

2 (22.2)

4 (57.1)

History of trauma or abuse, No. (%)

7 (77.8)

6 (66.7)

7 (77.8)

6 (85.7)

Previous psychotherapy, No. (%)

6 (66.7)

6 (66.7)

5 (55.6)

3 (42.9)

Treated with psychotropic medications, past
and current, No. (%)

8 (88.9)

8 (88.9)

9 (100.0)

5 (71.4)

Benzodiazepines, No. (%)

6 (66.7)

5 (55.6)

6 (66.7)

2 (28.6)

Antidepressants, No. (%)

4 (44.4)

7 (77.8)

6 (66.7)

5 (71.4)

Antipsychotics, No. (%)

2 (22.2)

1 (11.1)

0

2 (28.6)

Clinical diagnosis, made by neuropsychiatric
examination and SCID, No. (%)b

Clinical factors, from history at baseline

On AEDs at baseline, No. (%)

5 (55.6)

Total lifetime AEDs, mean (SD), No.

2.67 (1.2)

5 (55.6)

7 (77.8)

4.00 (3.4)

3 (42.9)

3.11 (1.9)

4.00 (1.6)
2.2 (3.4)

Time from NES onset to NES diagnosis, y
Mean (SD)

3.7 (4.6)

1.4 (1.3)

5.6 (5.6)

Median (range)

1.0 (0.0-10.6)

1.6 (0.0-3.7)

3.1 (0.2-14.4) 0.5 (0.1-9.5)

Time from NES diagnosis to NES
treatment, y
Mean (SD)

0.4 (0.7)

1.5 (2.6)

1.4 (2.2)

0.6 (1.2)

Median (range)

0.2 (0.0-2.1)

0.3 (0.0-7.0)

0.5 (0.1-6.9)

0.2 (0.04-3.4)

Abnormal neurological examination findings
at enrollment, No. (%)

7 (87.5)

5 (55.6)

7 (87.5)

7 (100.0)

Abnormal brain MRI findings, past or at
enrollment, No. (%)

3 (60.0)

4 (50.0)

4 (57.1)

3 (50.0)

30-min EEG tracing or video EEG findings,
No. (%)
Interictal epileptiform activity
Slowing, only EEG abnormality

0

0

0

0

2 (28.6)

1 (14.2)

0

Biological family history of seizures

2 (22.2)

3 (33.3)

2 (22.2)

3 (42.9)

History of head injury

3 (37.5)

5 (55.6)

6 (66.7)

7 (100.0)

in the analyses. As a conservative effort, only 2-tailed tests and
confidence intervals were calculated.

Results
A total of 81 patients met all inclusion and no exclusion criteria
and were eligible from all 3 sites. Of the 81 eligible participants,
38 (46.9%) provided written informed consent for the study and
43 (53%) refused to participate (similar to rates of prior trials10).
1000

1 (14.2)

Abbreviations: AEDs, antiepileptic
drugs; CBT-ip, cognitive behavioral
therapy informed psychotherapy;
EEG, electroencephalography;
MRI, magnetic resonance imaging;
NES, nonepileptic seizures;
SCID, Structured Clinical Interview
for DSM-IV Disorders; TAU, treatment
as usual.
a

There were no significant
differences between treatment
groups in demographic and
descriptive variables collected at
enrollment.

b

Not mutually exclusive.

c

Seven patients have 2 different
mood disorders.

d

Four patients have 5 different
anxiety disorders, 5 patients have
4 different anxiety disorders,
3 patients have 3 different anxiety
disorders, 10 patients have
2 different anxiety disorders, and
6 patients have 1 anxiety disorder.

Three patients dropped out the day after signing consent, 31
completed all sessions and surveys, and 34 were included in the
mixed modeling analysis to account for an intention-to-treat approach (Figure 1). The greatest reasons for screening failures included individuals not being eligible because of current comorbid epilepsy (n = 179 [35.2%]), lack of access (n = 111 [21.8%]),
lack of seizure in the month prior to assessment (n = 29 [5.7%]),
and not having a video EEG–confirmed diagnosis (n = 26 [5.1%]).
Demographic characteristics, clinical factors, and clinical diagnoses are described in Table 1. There were no between–
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Table 2. Within-Treatment Condition Monthly Seizure Count Change
Posttreatment/Pretreatment Ratio
of Seizures, Mean (SE) [95% CI]

Reduction, %

.01

0.49 (0.1) [0.28 to 0.84]

51.4

−2.69

.008

0.41 (0.1) [0.21 to 0.79]

59.3

−0.31 (0.2) [−0.6 to 0.03]

−1.78

.08

0.74 (0.1) [0.52 to 1.03]

26.5

−0.40 (0.3) [−1.0 to 0.2]

−1.32

.19

0.67 (0.2) [0.37 to 1.21]

33.8

Patients, No.

Slope (SE) [95% CI]

T438

CBT-ipa

9

−0.72 (0.3) [−1.3 to −0.2]

−2.95

CBT-ip with sertralinea

9

−0.90 (0.3) [−1.6 to −0.2]

Sertraline

9

Treatment as usual

7

Treatment

a

Abbreviation: CBT-ip, cognitive behavioral therapy informed psychotherapy.

P Value

Statistically significant differences.

Figure 2. Monthly Trajectory of Seizure Counts by Treatment Condition
20

CBT-ip and sertraline
Sertraline

Mean Seizure Count, No.

15

Treatment as usual
CBT-ip
10

5

0
0

2

4

Time in Trial, mo

treatment group significant differences in demographic variables at enrollment. Sample sizes did not allow for betweensite analysis.

Primary Analysis of Treatment Effect on Seizure Frequency
Within-treatment condition analyses indicate significant reductions in the number of monthly seizures reported by patients in the CBT-ip condition and the CBT-ip with sertraline
condition relative to prospective baseline. Specifically, patients in the CBT-ip condition reported 51.4% fewer total
monthly seizures (P = .01) and patients in the CBT-ip with sertraline condition reported 59.3% fewer total monthly seizures (P = .008). Patients in the sertraline condition experienced 26.5% fewer total monthly seizures; however, this was
not statistically significant (P = .08). Patients in the TAU condition did not experience a significant change in the total
monthly number of seizures (P = .19). The pilot study was not
powered to detect between-group differences and was designed for within-group analyses. A main effect was observed for time when modeling total seizures (F1,30 = 17.44;
P < .001). No interaction effect or between–treatment condition seizure trajectories were observed. These findings are summarized in Table 2 and Figure 2.
The majority of patients in the 3 treatment conditions reported a 50% or greater reduction in the number of seizures
from enrollment to exit (CBT-ip, 55.6%; CBT-ip with sertraline, 66.7%; sertraline, 55.6%). No change in seizures occurred in the CBT-ip (n = 1), CBT-ip with sertraline (n = 1), serjamapsychiatry.com

Lines indicate functions of the mean
weekly seizure count; shaded areas,
variation corresponding to each line
(treatment arm). Cognitive
behavioral therapy informed
psychotherapy (CBT-ip) with
sertraline, P = .008; CBT-ip only,
P = .01; sertraline only, P = .08; and
treatment as usual, P = .19. Median
time in the trial was 15 weeks, with a
median range from 14 weeks in the
sertraline group to 17 weeks in the
group receiving CBT-ip only and the
group receiving CBT-ip with
sertraline.

traline (n = 1), and TAU (n = 2) groups, and seizure increases
were reported in the CBT-ip (n = 0), CBT-ip with sertraline
(n = 1), sertraline (n = 4), and TAU (n = 2) groups. Several patients also reported seizure freedom (0 seizures) at the exit interview (CBT-ip, n = 3; CBT-ip with sertraline, n = 5; sertraline, n = 1; and TAU, n = 1 [excluding those with no seizures in
the prospective baseline period]). When comparing patients
who received CBT-ip with those who did not by combining conditions, the odds of achieving seizure freedom was 6.2 times
greater for those receiving CBT-ip relative to those not receiving CBT-ip (P = .06).
Regarding patient expectations, a model examining seizure counts given treatment arm, time, and level of positive
prognosis expectations (using a 1- to 5-point Likert scale at enrollment) did not yield a significant interaction effect. Thus,
it does not appear that the level of self-predicted positive expectation influenced the effect of time and treatment arm for
seizure count.

Treatment Effect on Secondary Outcomes
Secondary outcomes including depression, anxiety, somatic
symptoms, QOL, impulsivity, and psychosocial functioning
were examined within groups and between treatment conditions. Several between-group time-by-treatment interaction
effects and main effects for time and condition were observed in secondary measures (eTable 1 in the Supplement).
More importantly, results from multiple comparison tests indicate that when differences existed between treatment conJAMA Psychiatry September 2014 Volume 71, Number 9
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Table 3. Between-Treatment Difference on Secondary Measures (Linear Trend)a
Treatment

Linear Trend Difference (SE) [95% CI]

T116

P Value

Global Assessment of Functioning
CBT-ip vs CBT-ip with sertraline

37.5 (20.9) [−18.5 to 93.6]

1.8

.37

CBT-ip vs sertraline

44.4 (25.0) [−22.7 to 111.5]

1.8

.37

CBT-ip vs treatment as usualb

66.8 (23.3) [4.3 to 129.3]

2.9

.03

6.9 (21.4) [−50.6 to 64.4]

0.3

.75

CBT-ip with sertraline vs treatment as usual

29.2 (19.4) [−22.8 to 81.3]

1.5

.40

Sertraline vs treatment as usual

28.1 (23.8) [−35.7 to 91.8]

1.2

.48

CBT-ip with sertraline vs sertraline

Oxford Handicap Scale
CBT-ip vs CBT-ip with sertralineb

−4.2 (1.4) [−8.0 to −0.3]

−2.9

.02

CBT-ip vs sertralineb

−6.1 (1.9) [−11.3 to −0.9]

−3.1

.01

CBT-ip vs treatment as usualb

−6.3 (1.7) [−10.8 to −1.7]

−3.7

.002

CBT-ip with sertraline vs sertraline

−1.9 (2.0) [−7.2 to 3.4]

−1.0

.69

CBT-ip with sertraline vs treatment as usual

−2.1 (1.7) [−6.7 to 2.6]

−1.2

.69

Sertraline vs treatment as usual

−1.9 (2.2) [−7.7 to 4.0]

−0.9

.69

Clinical Global Impressions–Severity
CBT-ip vs CBT-ip with sertraline

−2.5 (2.8) [−9.9 to 4.9]

−0.9

.69

CBT-ip vs sertraline

−5.8 (2.4) [−12.2 to 0.6]

−2.4

.09

CBT-ip vs treatment as usualb

−7.2 (2.2) [−13.1 to −1.2]

−3.3

.01

CBT-ip with sertraline vs sertraline

−3.3 (3.0) [−11.4 to 4.9]

−1.1

.69

CBT-ip with sertraline vs treatment as usual

−4.6 (2.9) [−12.4 to 3.1]

−1.6

.44

Sertraline vs treatment as usual

−3.1 (2.5) [−9.9 to 3.8]

−1.2

.69

ditions, patients in the CBT-ip condition often improved more
than those in the MED condition, the TAU condition, or both.
The study was not designed to randomize patients stratified on secondary measures at baseline. Nevertheless, treatment arms were found to be equivalent across secondary measures at baseline, with the exceptions of scores on anxiety,
depression, and some somatic symptom scales, including the
Beck Anxiety Inventory (F3,24 = 3.43; P = .03), Beck Depression Inventory–II (F3,30 = 4.38; P = .01), Hamilton Depression
Rating Scale (F3,24 = 3.25; P = .04), Longitudinal Interval Follow-up Evaluation–Range of Impaired Functioning Tool
(F3,30 = 2.92; P = .05), and Side Effects Profile (F3,30 = 4.38;
P = .01). Multiple comparisons indicate that participants in the
CBT-ip with sertraline group reported lower scores than those
in the TAU group for the Beck Anxiety Inventory, Beck Depression Inventory–II, and Side Effects Profile; those in the CBT-ip
with sertraline group also reported lower scores on the Beck
Depression Inventory–II than those in the sertraline group. Multiple comparisons did not indicate differences between treatment arms for the Longitudinal Interval Follow-up Evaluation–
Range of Impaired Functioning Tool and Hamilton Depression
Rating Scale. As a conservative effort, the potential moderating influence of these baseline differences on seizure count was
therefore examined. However, no significant interactions were
observed, indicating that the baseline differences on secondary measures did not have a moderating influence on seizure
count (Table 3).
Linear trend estimates and standard errors on secondary
outcomes were examined within each treatment condition relative to enrollment spanning 4 assessment periods (ie, baseline [enrollment], intervention initiation, midpoint, and final
[exit]). Significant improvements were observed on most sec1002

Abbreviation: CBT-ip, cognitive
behavioral therapy informed
psychotherapy.
a

Holm-Bonferroni method was used
for tests of multiple comparisons.

b

Statistically significant.

ondary outcomes for patients in the CBT-ip condition and several outcomes for patients in the CBT-ip with sertraline condition. No significant improvements were observed for patients
in the sertraline condition. No measures improved in the patients in the TAU condition. As this is a pilot study, trends toward significance were also noted. Additionally, baseline and
exit differential effect sizes were calculated for each condition. These results are summarized in eTable 2 in the Supplement, including categorical changes for the Ways of Coping
Questionnaire. The eFigure in the Supplement includes mean
plots of outcomes for secondary measures by treatment condition over the 4 assessment periods.
Qualitative reports from patient exit interviews revealed
common themes found in the therapy groups, including appreciation for newly acquired coping skills (even if seizures did
not abate completely), positive effects on relationships and activities, and medication adverse effects.
Lastly, generalized linear mixed models assuming a Poisson distribution comparing the number of emergency department visits prior to and during the trial (standardized by month)
detected a significant time × treatment effect (F3,60 = 4.81;
P = .005). More importantly, Bonferroni multiple comparisons indicate that participants in the CBT-ip condition reported significantly fewer visits to the emergency department during the trial relative to baseline (estimated difference
[SE], −1.3 [0.2]; t60 = 5.43; P < .001).

Discussion
In this pilot multisite RCT, a time-limited CBT-ip–based manualized intervention for PNES administered by trained clini-
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cians resulted in significant reduction in PNES and improved
comorbid psychiatric symptoms, QOL, and functioning. The
psychotherapy arm showed significant improvements compared with TAU, which showed no improvements in primary
or secondary outcomes. The secondary goal was to assess the
feasibility of disseminating the treatment10 to other locations
and mental health clinicians.
Some studies of combined treatments for depression and
anxiety showed greater benefit of combined psychotherapy and
medication than either treatment alone.22,23 The greater overall secondary outcome improvements in the CBT-ip–only arm,
compared with the CBT-ip with sertraline arm, was unexpected. Given the trend in seizure reduction of 26.5% in the
sertraline group (P = .08), we hypothesize that adding a selective serotonin reuptake inhibitor provides some reduction in
seizures,13 but medication adverse effects in this already somatically focused population may have mitigated its impact
on the comorbidities. The selective serotonin reuptake inhibitor effects that may impact a fear-extinction domain24 could
have a differential effect on somatic symptoms. Qualitative
review of patients on medication perspectives revealed
statements such as, “My seizures are better, but I’ve had more
upset stomach on the medication.” The adverse effect–
constitutional symptoms from the medication may have
contributed to less reduction in the anxiety and depression
scores than in the CBT-ip–only arm.
In addition to significant seizure reduction with the therapy,
comorbid depression, anxiety, dissociation, and somatic symptoms also improved significantly. Given that comorbidities are
the rule in the PNES population, the study was designed to take
all comers; thus, we intentionally did not restrict inclusion based
on common comorbidities (eg, posttraumatic stress disorder,
anxiety, depression, Axis II traits and disorders, trauma history, family dysfunction) for external validity. The consistency
of multiple comorbidities and stressors composes, in effect, the
homogeneity of PNES. This intervention therefore treats patients with PNES, with all of their heterogeneities.25
Functioning, coping mechanisms, and QOL also improved. Patients in the CBT-ip (both alone and with sertraline) arms used unhealthy coping techniques at enrollment,
and by exit they were using healthy techniques. The CBT informed therapy differs from supportive therapy, addresses traditional targets of CBT techniques (thoughts and schema), and
incorporates interpersonal (targeting communication), mindfulness (targeting distress tolerance), and dynamic (targeting
developmental) therapy methods that help develop healthy
coping.26 Drawing important techniques from other modalities accounts for its reach beyond solely treating seizures and
differentiates this therapy from other treatments.27 Although
not powered to do so, the CBT-ip–only arm was significantly
better than TAU for global functioning, Oxford Handicap Scale
scores, and Clinical Global Impressions–Severity scores. Given
improvements in the treatment groups contrasted against no
improvements in the TAU group, the differences do not appear to be an effect of the natural course of the illness when
patients had received other treatments.28,29 That the effect was
demonstrated with a small sample underscores the impact of
the intervention.
jamapsychiatry.com

Patients with seizures have travel limitations, and some
patients receiving CBT-ip had to reschedule appointments because of transportation or weather. As was done in the pilot
open-label trial,10 Clinical Video Telehealth was used successfully again by the Rhode Island Hospital for 2 patients for sessions in this RCT when they had travel difficulties, and this did
not affect participation or outcomes. The Veterans Affairs Medical Centers use Clinical Video Telehealth30 for veterans with
PNES. Tele–mental health care currently is not reimbursed by
many insurance providers. Given the expense of this disorder in patients who receive inappropriate treatment,31-34 Clinical Video Telehealth has the potential to improve access to care
for civilians and should be assessed in a formal trial. Overcoming diagnosis and treatment obstacles (eg, transportation,
providing treatment in remote areas), thereby addressing treatment gaps, could greatly reduce costs for the difficult-totreat population. In this RCT, emergency department visits
were significantly reduced in the CBT-ip arm, building on
studies showing that identifying PNES decreases emergency
department use.35
Our study gives the first level 1 data for PNES. Regarding
level of evidence to inform evidence-based treatment36 for
PNES, while numerous open-label and uncontrolled trials are
in the literature, to our knowledge the only 2 pilot RCTs for
PNES include a traditional CBT approach (level 3 data)37 or a
pharmacologic approach (level 2 data).13
Limitations of the study were related to its sample size. This
study was not an efficacy trial. Despite not being powered for
differences between groups, however, the effect size demonstrated significant within-group reductions in seizures and differences between CBT-ip and TAU on secondary measures.
While no demographic differences were present between
groups, the CBT-ip with sertraline group and the TAU group
showed baseline differences in anxiety, mood, and somatic
symptom scale scores. Despite these differences, all groups
were in the range of moderate to severe symptoms on scales
at baseline. A larger sample size would likely diminish these
differences with randomization. Furthermore, no baseline differences were observed for the primary outcome of seizure and
most of the secondary variables, thus indicating that randomization occurred for these variables. Despite baseline differences in anxiety, depression, and somatic symptoms in 2 arms,
these few differences did not moderate seizure count for the
4 arms. The trial was not double blind because it was not possible with some receiving CBT-ip, some receiving sertraline,
some receiving CBT-ip with sertraline, and some receiving TAU.
Blinding of the raters to treatment arm, however, provided
blinded assessments. To reflect standard medical care in TAU,
the study arms differed in that the TAU group received contact with mental health clinicians less frequently than the
CBT-ip and CBT-ip with sertraline arms. Biweekly follow-up
provided a modified exposure control (every 2 weeks in TAU
vs weekly in therapy arms). Biweekly contact with the patients in the TAU condition was more frequent than the typical follow-up once every 1 to 3 months but was less frequent
than in other arms. Contact was made, however, at the same
frequency as the sertraline arm. Given the biweekly follow-up in both groups, with the sertraline arm showing some
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improvements and the TAU arm showing no change or worsening, the differences are not attributable to less frequent contact in the TAU arm. The duration of follow-up for this study
was linked to the treatment. We observed differences with CBTip; however, whether such responses are sustained over time
(ie, whether freedom of PNES is maintained) is being assessed. The durability of the response will be assessed with 12month follow-up examinations. Future trials could likewise assess outcomes of longer duration, eg, 6 or 12 months.
This study was a prelude to a trial planned to include a
larger number of participants and outcome measures different from the traditional 50% responder rate (eg, seizure freedom). Choosing an appropriate outcome measure is germane
to the overall success of such a study. While a 50% responder
rate is the usual outcome measure in epilepsy regulatory trials,
such an outcome measure may not be the most optimal one
for PNES.38 Thus, while providing important outcome data, this
study also addressed several potential difficulties of conducting such trials in the PNES population, including participant
recruitment and retention (good retention aided by contact
with participants), choice of primary and secondary outcome
measure(s), providing uniform treatments and intervention
across centers, and training individuals on provision of interventions and collection of outcome data. While the study enrolled a relatively small number of participants, considering
the financial limitations and the fact that significant re-
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